P243 Changes in the therapeutic management of inflammatory bowel disease in the biological era – a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

M. Zhao1, M. Lördal2, E. Langholz3, T. Knudsen4, M. Voutilainen5, M.L. Høivik6, B. Moum7, B. Saebo8, P. Haiko9, C. Malmgren10, M. Coskun11, H.O. Melberg12, J. Burisch13

1Hvidovre Hospital- Copenhagen University, Gastrointestinal Unit, Hvidovre, Denmark, 2Danderyds Hospital, Gastroenterology and Hepatology, Stockholm, Sweden, 3Herlev Hospital, Department of Medical Gastroenterology, Herlev, Denmark, 4Department of Medicine- Hospital South West Denmark, Department of Regional Health Research- University of Southern Denmark, Odense, Denmark, 5University of Turku, Department of Gastroenterology, Turku, Finland, 6University Hospital, Department of Gastroenterology, Oslo, Norway, 7Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 8Takeda AS, Medical Affairs, Asker, Norway, 9Takeda Oy, Medical Affairs, Helsinki, Finland, 10Takeda Pharma AB, Medical Affairs, Stockholm, Sweden, 11Takeda A/S, Medical Affairs, Taastrup, Denmark, 12Institute of Health and Society- University of Oslo, Department of Health Management and Health Economics, Oslo, Norway, 13Hvidovre University Hospital, Gastrounit- Medical Division, Hvidovre, Denmark


The use of biologic therapy has increased significantly during the last decade. In 2015, one in three Crohn’s disease (CD) patients and one in five ulcerative colitis (UC) patients had received biologics within 2 years of diagnosis 1 in Denmark (DEN), Sweden (SWE) and Norway (NOR). Whether this change in treatment strategy has resulted in changes in the use of conventional drugs (5-aminosalicylates [5-ASA], immunomodulators [IM] or corticosteroids) remains unknown. An aim of this study was to investigate the use of these drugs in the biological era.1 Høivik ML et al. Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study, Submitted to ECCO 2020.


A total of 67,758 incident IBD patients (42,894 UC, 24,864 CD) diagnosed between 2010 to 2017 were included in a nationwide cohort in DEN, NOR and SWE. Information on drug treatment was extracted from the National Patient Registries and the National Prescription Registries. Patients were required to have at least 1-year of follow-up post-diagnosis; results are limited to patients diagnosed between 2010 to 2016, inclusive.


During 2010 to 2016, cumulative exposure to 5-ASA in CD patients at 2 years after diagnosis declined from 19.0%, 39.0% and 50.5% in 2011 to 16.3%, 31.1% and 39.6% in 2016 in DEN, NOR and SWE, respectively (p < 0.001). The opposite trend was observed in UC where 87.3–91.1% received 5-ASA within 2 years in 2015 compared with 75.8–87.3% in 2011 (p < 0.001) (Figure 1). In all countries, corticosteroid use remained stable in CD with more than half of patients receiving corticosteroids within 2 years of diagnosis. In UC, corticosteroid use within 2 years of diagnosis increased in NOR from 42.2% in 2011 to 51.6% in 2015 (p < 0.001) but remained stable in DEN and SWE (Figure 2). The use of IM within 2 years increased in CD patients in NOR and SWE from 36.5% and 40.8% in 2010 to 51.3% and 52.1% in 2015 (p < 0.001). IM were less frequently used in UC but increased similarly from 14.0% and 21.1% in 2010 to 22.5% and 26.4% in 2015 (p < 0.001). In DEN, IM use remained stable over time (Figure 3).


The use of 5-ASA declined over time in patients diagnosed with CD but increased over time in patients diagnosed with UC. Corticosteroid use remained stable in CD but increased over time in UC patients in NOR. The increasing and earlier use of biologics was accompanied by increasing use of IM in all countries. While this could suggest a more aggressive treatment approach, differences in treatment practices across countries might contribute to these findings. The impact of changes in treatment strategies on disease outcomes remains to be shown.